SAN DIEGO, April 28, 2014 (GLOBE NEWSWIRE) -- Receptos Inc. (Nasdaq:RCPT) today announced that Company personnel will deliver two scientific poster presentations regarding its lead program, RPC1063, at the annual meeting of the American Academy of Neurology (AAN) in Philadelphia, PA. RPC1063 is the Company's sphingosine 1-phosphate 1 receptor (S1P1R) modulator in Phase 3 development for relapsing multiple sclerosis (RMS) and Phase 2 development for inflammatory bowel disease (IBD).
Help employers find you! Check out all the jobs and post your resume.
